April 23, 2019
Researchers from Baylor College of Medicine and Texas Children’s Hospital are exploring “non-engineered” T-cell therapies that are easier to manufacture and able to target multiple antigens.
April 3, 2019
A recent report by CBRE Research analyzing U.S. life science clusters found that Houston, Texas is the third-fastest growing life science market from 2014 to 2017.
March 29, 2019
With the help of Marker's technology, a population of T-cells attacks multiple cancer targets and works to activate a patient's immune system to trigger anti-tumor activity.
March 15, 2019
DLBCL data was particularly impressive. Patients who were third and fourth line refractory and relapsed post-transplant are experiencing durable and long responses with some now five years in remission.
January 4, 2019
The Houston, Texas-based immuno-oncology group gave an update on five clinical trials.
December 12, 2018
Marker Therapeutics has emerged out of a merger with Tapimmune to push forward new cell-based cancer vaccines.
November 16, 2018
The U.S. Department of Defense (DoD) has awarded Mayo Clinic researchers $11 million to conduct a Phase 2 trial investigating the TPIV110 vaccine, in combination with Herceptin (trastuzumab), as a therapy for women with HER2-positive breast cancer.
October 18, 2018
The company is the product of a merger between TapImmune and Marker Therapeutics that completed on Oct 17th, 2018 and on Thursday, October 18th begins trading under the ticker (NASDAQ: MRKR), retiring TapImmune's ticker (TPIV).
October 10, 2018
The Department of Defense awarded more than $11 million for this Jacksonville study.